Antibiotic market to reach US$ 74.07 billion by 2033; FDA approves GSK’s Blujepa for uncomplicated UTIs

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

Norvir

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

50 API Suppliers, 23 USDMF, 12 CEP/COS, 1 JDMF, 8 EU WC, 3 KDMF, 8 NDC API, 27 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

343 Drugs in Development

343 Drugs in Development

INTERMEDIATES

9 Intermediate Suppliers

9 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

135 FDF Dossiers, 41 FDA Orange Book, 42 Europe, 7 Canada, 5 Australia, 25 South Africa, 15 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 12.5MG;75MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 100MG;25MG, TABLET;ORAL - 200MG;50MG, TABLET;ORAL - 100MG

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 Minakem, 3 Rochem International Inc, 1 SPI Pharma, 10 DKSH, 1 PMC Isochem, 1 Pharm-RX Chemical, 6 Boai NKY Pharmaceuticals Ltd, 3 Gangwal Healthcare, 8 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 5 Kirsch Pharma, 4 ACG Worldwide, 7 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 2 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Ashland, 17 BASF, 2 Bioplus Life Sciences, 1 CD Formulation, 1 Clariant, 12 Corel Pharma Chem, 1 Finar, 13 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 4 Ideal Cures, 11 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 4 Microlex e.U, 2 Nanjing Bold Chemical, 1 Nitika Pharmaceutical Specialities, 4 Novo Excipients, 2 Pharmatrans-Sanaq, 3 Pluviaendo, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 3 Roquette, 15 Seppic, 2 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Sigachi Industries, 1 Symrise, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 2 Valens Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

46 Coating Systems & Additives, 34 Solubilizers, 30 Fillers, Diluents & Binders, 26 Parenteral, 20 Topical, 20 Film Formers & Plasticizers, 19 Controlled & Modified Release, 18 Thickeners and Stabilizers, 17 Emulsifying Agents, 13 Taste Masking, 12 Direct Compression, 12 Lubricants & Glidants, 11 Granulation, 10 API Stability Enhancers, 9 Empty Capsules, 8 Surfactant & Foaming Agents, 5 Rheology Modifiers, 5 Co-Processed Excipients, 5 Disintegrants & Superdisintegrants, 4 Coloring Agents, 4 Vegetarian Capsules, 2 Chewable & Orodispersible Aids

DIGITAL CONTENT

2 Data Compilation #PharmaFlow, 2 Stock Recap #PipelineProspector, 156 News #PharmaBuzz

GLOBAL SALES INFORMATION

11 US Medicaid Prescriptions, 10 Regulatory FDF Prices, 18 Annual Reports

MARKET PLACE

25 APIs, 9 FDF Dossiers

PATENTS & EXCLUSIVITIES

29 US Patents, 57 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 3 Others

ANALYTICAL

2 BioAnalytical Methods

2 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Certificate Holder	Certificate No.	Substance	Issue Date	Status	Type	End Date	Substance No.
29/11/2025	AbbVie Inc	U.S.A	AbbVie Inc. North Chicago US	R1-CEP 2012-397 - Rev 00	Ritonavir	2019-09-19	Valid	Chemical		2136
29/11/2025	Anhui Biochem Pharmaceutical	China	ANHUI BIOCHEM PHARMACEUTICAL CO., LTD. Fuyang CN	CEP 2022-394 - Rev 00	Ritonavir	2024-12-17	Valid	Chemical		2136

Norvir

Norvir

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

50 API Suppliers

23 USDMF

12 CEP/COS

1 JDMF

8 EU WC

3 KDMF

8 NDC API

27 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

343 Drugs in Development

INTERMEDIATES

9 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

135 FDF Dossiers

41 FDA Orange Book

42 Europe

7 Canada

5 Australia

25 South Africa

15 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 12.5MG;75MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 100MG;25MG

TABLET;ORAL - 200MG;50MG

TABLET;ORAL - 100MG

RELATED EXCIPIENT COMPANIES

2 EUROAPI

1 Minakem

3 Rochem International Inc

1 SPI Pharma

10 DKSH

1 PMC Isochem

1 Pharm-RX Chemical

6 Boai NKY Pharmaceuticals Ltd

3 Gangwal Healthcare

8 Nanjing Well Pharmaceutical

1 Shanghai Minbiotech

5 Kirsch Pharma

4 ACG Worldwide

7 Actylis

1 Aeon Procare

1 Alcedo Pharmachem

2 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

1 Ashland

17 BASF

2 Bioplus Life Sciences

1 CD Formulation

1 Clariant

12 Corel Pharma Chem

1 Finar

13 Gangwal Chemicals

1 Huzhou Sunflower Pharmaceutical

4 Ideal Cures

11 Kerry

3 Kima Chemical

6 Lonza Capsugel

4 Microlex e.U

2 Nanjing Bold Chemical

1 Nitika Pharmaceutical Specialities

4 Novo Excipients

2 Pharmatrans-Sanaq

3 Pluviaendo

1 Qianhao Chemical (Hebei) Co., Ltd

2 Qualicaps

3 Roquette

15 Seppic

2 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

2 Sigachi Industries

1 Symrise

TABLET;ORAL - 12.5MG;75MG;50MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - EQ 200MG BASE;8.33MG;50MG;33.33MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - 100MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons